Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
Introduction: Surgery is the only definitive therapy for neuroendocrine tumours (NET). In number of small intestine NET first symptom is ileus or perforation, lifesaving surgical procedures applied. Such cases have significant risk of recurrence.
Conference:
Presenting Author: Hajac �
Authors: Hajac L, Szewczyk K, Piwkowski P, Chowaniec Z, Mazurak J,
Keywords: radio guided surgery, Neuroendocrine tumour, early relapse,
Introduction: Most pancreatic neuroendocrine tumours (PanNETs) are non-functioning. Previously, we demonstrated that small, MEN1-only mutated α-like PanNETs can be distinguished from larger ADM (mutated in ATRX, DAXX and MEN1) PanNETs based on epigenetic profiles. ADM PanNETs have shorter disease-free survival and a higher relapse risk. However, their therapeutic responses vary, underscoring group heterogeneity. ADM PanNETs remain insufficiently characterised, with potential subtype-specific progression drivers with implications for treatment choice and clinical outcome.
Conference:
Presenting Author: Avanthay S
Authors: Avanthay S, Di Domenico A, Kirchner P, Bräutigam K, Chouchane A,
Keywords: pancreas, epigenetics, progression, metastasis, DAXX, ATRX, Pan NET,
#4473 Somatostatin analogue delayed the recrudescence of stomach NET: A real-world study
Introduction: Type 1 gastric NENs (g-NENs) are common and relapse easily. Somstostatin analogues (SSAs) can inhibit gastrin secretion and cell proliferation. While the usage of SSAs in g-NENs is still controversial.
Conference:
Presenting Author: Cai W
Authors: Cai W, Zhang J, Ge W, Hu H,
Keywords: somatostatin analogue, Type 1 gastric NEN, real-world study,
Introduction: Our multi-centre, prospective, open-label, two-arm parallel group, randomised, controlled, phase III study will address the efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia.
Conference:
Presenting Author: Eilsberger F
Authors: Eilsberger F, Luster M, Rau J, Avci H, Schade-Brittinger C,
Keywords: adjuvant therapy, neuroendocrine neoplasia, small intestine, peptide receptor radionuclide therapy, PRRT,
Introduction: Neuroendocrine neoplasms (NENs) consist of neuroendocrine tumours and neuroendocrine carcinomas, which are rare malignancies found in various anatomical sites, including the gastrointestinal tract, pancreatic islets, lungs, and adrenal glands. Poorly differentiated NECs are classified as high-grade carcinomas that bear resemblance to small-cell lung cancer; however, these patients experience a high risk of relapse and demonstrate a limited response to additional systemic therapies. Adrenocortical carcinoma (ACC) is another rare cancer and currently, no targeted therapies have demonstrated significant effectiveness for this condition. Preclinical investigations have indicated that Delta-like non-canonical notch ligand 1 (DLK1) is expressed in various neuroendocrine neoplasms, including ACC, SCLC, neuroblastoma, pheochromocytoma, and paraganglioma.
Conference:
Presenting Author: Del Rivero J
Authors: Del Rivero J, Glod J, Magee T, Cooper K, Rivero A,